When the medication stops, those underlying signals resume
Generally, individuals with a body mass index (BMI) of 30 or higher or a BMI of 27 or higher with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol, may qualify for Semaglutide GLP-1 treatment
In many people with obesity or type 2 diabetes, GLP-1 levels are lower or not as effective
If a consult feels rushed, overly salesy, or promises guaranteed results, thats a sign to pause
The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs. The announcement notes that the price decrease will only impact the list price
Approval is expected in 2026